Hebei Huachen Pharmaceutical Group Co., Ltd.

Primary objective: To evaluate the bioequivalence of dotenorazole tablets (licensed by Hebei Huachen Pharmaceutical Group Co., Ltd.) under fasting and postprandial conditions using dotenorazole tablets (trade name: URECE®, strength: 2 mg) (licensed by Fuji Pharmaceutical Co., Ltd.) as the test formulation and dotenorazole tablets (trade name: URECE®, strength: 2 mg) as the reference formulation in a single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover clinical trial. Secondary objective: To observe the safety of the test and reference formulations in healthy trial participants.

Primary Objective: To investigate the absorption rate and extent of absorption of oseltamivir phosphate capsules (test formulation T, manufactured by Hebei Huachen Pharmaceutical Group Co., Ltd., strength: 75 mg) and oseltamivir phosphate capsules (reference formulation R, licensed by Roche Pharma (Schweiz) AG, manufactured by Delpharm Milano S.r.l., and packaged by Roche Pharmaceuticals Shanghai Co., Ltd., trade name: Tamiflu®, strength: 75 mg) under fasting/postprandial conditions in healthy participants, and to evaluate their bioequivalence. Secondary Objective: To observe the safety of the test formulation oseltamivir phosphate capsules and the reference formulation oseltamivir phosphate capsules (Tamiflu®) in healthy participants.

Primary objective: To evaluate the efficacy of different doses of topiramate tablets in Chinese hyperuricemia patients with or without gout; Secondary objective: To evaluate the safety of topiramate tablets in Chinese hyperuricemia patients with or without gout.